Rallybio Corporation filed a current report on Form 8-K on November 10, 2026, disclosing a one-for-two reverse stock split of its common stock set to take effect at 12:01 a.m. Eastern Time on November 20, 2026, in connection with its planned merger with Avenzo Therapeutics, Inc.

Key Highlights

  • Reverse split ratio: The Board of Directors, with Avenzo's mutual agreement, approved a one-for-two reverse stock split on November 8, 2026.
  • Effective date: The reverse stock split is expected to become effective at 12:01 a.m., Eastern Time, on November 20, 2026.
  • Share count impact: Outstanding shares are expected to decrease from approximately 5.6 million to approximately 2.8 million, prior to the closing of the merger.
  • Par value unchanged: The par value of common stock will remain $0.0001 per share after the reverse stock split.
  • Post-merger identity: Following the merger closing and applicable Nasdaq approvals, the company plans to change its name to Avenzo Therapeutics, Inc. and trade under the symbol "AVZO" with CUSIP number 053928 107.
  • Fractional shares: No fractional shares will be issued; stockholders entitled to fractional shares will receive cash equal to the fair market value based on the closing price on the effective date.
  • Exchange agent: Computershare Trust Company, N.A. is acting as the exchange agent and transfer agent for the reverse stock split.

Rallybio Discloses Reverse Split Terms and Merger-Related Name Change Plans

According to the filing, Rallybio Corporation (NASDAQ:RLYB) announced on November 10, 2026 that it will carry out a one-for-two reverse stock split of its issued and outstanding common stock. The action is connected to the Agreement and Plan of Merger and Reorganization dated May 31, 2026, among Rallybio, Avenzo Therapeutics, Inc., and Farmington Merger Sub, Inc., a wholly owned subsidiary of Rallybio. The company disclosed that stockholders, at the Annual Meeting held on November 4, 2026, approved an amendment to the Amended and Restated Certificate of Incorporation permitting a reverse split at a ratio ranging from one-for-two to one-for-nine, inclusive, with the final ratio to be mutually determined by Rallybio and Avenzo.

The filing states that every two issued and outstanding shares of common stock will automatically be combined into one share at the effective time. The reverse stock split will not change the authorized number of shares of common stock, and proportionate adjustments will be made to shares underlying outstanding pre-funded warrants and equity awards, including, where applicable, their exercise prices, and to shares reserved under equity incentive plans. The company noted that the reverse stock split will affect all stockholders uniformly and will not by itself alter any stockholder's percentage interest in the company's equity, except to the extent fractional shares result in cash payments.

Stockholders holding shares in book-entry form are not required to take any action, according to the filing. Those holding physical certificates will receive instructions from Computershare regarding the exchange process. The filing noted that additional information is available in the company's proxy statement/prospectus included in its Form S-4 registration statement, which was declared effective by the SEC on October 15, 2026. The filing contains forward-looking statements, which the company characterized as subject to risks and uncertainties, including the risk that the merger will be delayed or not completed.

What Was Disclosed

Rallybio filed an 8-K disclosing a one-for-two reverse stock split effective November 20, 2026, reducing outstanding shares from approximately 5.6 million to approximately 2.8 million, alongside plans to rename the company and trade as "AVZO" after the merger closes.